Novel diindolylmethane derivatives based NLC formulations to improve the oral bioavailability and anticancer effects in triple negative breast cancer

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 108, Issue , 2016, Pages 168-179

  Godugu, Chandraiah ^a,b   Doddapaneni, Ravi ^a   Safe, Stephen H ^c   Singh, Mandip ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Diindolylmethane; Nano structured lipid carriers; Oral bioavailability; Triple negative breast cancer (TNBC)

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CD31 ANTIGEN; CYCLIN D1; DIM 10; DIM 14; INDOLE DERIVATIVE; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; UNCLASSIFIED DRUG; VASCULOTROPIN; DIINDOLYLMETHANE; DRUG CARRIER; LIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CACO 2 CELL LINE; CELL MEMBRANE PERMEABILITY; CELL MIGRATION ASSAY; CELL VIABILITY; CLONOGENIC ASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PH; PROTEIN EXPRESSION; RAT; SOLUBILITY; SUSTAINED DRUG RELEASE; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL INOCULATION; TUMOR VOLUME; WEIGHT CHANGE; WESTERN BLOTTING; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CACO-2 CELL LINE; CHEMISTRY; DOG; DRUG DELIVERY SYSTEM; DRUG SCREENING; HUMAN; MALE; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PERMEABILITY; SPRAGUE DAWLEY RAT; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CELL LINE, TUMOR; DOGS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INDOLES; LIPIDS; MALE; MICE; MICE, NUDE; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84988019856     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2016.08.006     Document Type: Article

References (36)

1. [1] Ahmad, M.Z., Alkahtani, S.A., Akhter, S., Ahmad, F.J., Ahmad, J., Akhtar, M.S., Mohsin, N., Abdel-Wahab, B.A., Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: current state-of-the-art. J. Drug Target., 2015, 1–21.
2. [2] Andey, T., Patel, A., Jackson, T., Safe, S., Singh, M., 1,1-Bis (3′-indolyl)-1-(p-substitutedphenyl)methane compounds inhibit lung cancer cell and tumor growth in a metastasis model. Eur. J. Pharm. Sci. 50:2 (2013), 227–241.
3. [3] Beloqui, A., Solinis, M.A., Gascon, A.R., del Pozo-Rodriguez, A., des Rieux, A., Preat, V., Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J. Control. Release 166:2 (2013), 115–123.
4. [4] Boakye, C.H., Doddapaneni, R., Shah, P.P., Patel, A.R., Godugu, C., Safe, S., Katiyar, S.K., Singh, M., Chemoprevention of skin cancer with 1,1-Bis (3′-indolyl)-1-(aromatic) methane analog through induction of the orphan nuclear receptor, NR4A2 (Nurr1). PLoS ONE, 8(8), 2013, e69519.
5. [5] Bregoli, L., Movia, D., Gavigan-Imedio, J.D., Lysaght, J., Reynolds, J., Prina-Mello, A., Nanomedicine applied to translational oncology: A future perspective on cancer treatment. Nanomedicine 12:1 (2015), 81–103.
6. [6] Elmowafy, M., Samy, A., Raslan, M.A., Salama, A., Said, R.A., Abdelaziz, A.E., El-Eraky, W., El Awdan, S., Viitala, T., Enhancement of bioavailability and pharmacodynamic effects of Thymoquinone Via Nanostructured Lipid Carrier (NLC) formulation. AAPS PharmSciTech 17:3 (2015), 663–672.
7. [7] Godugu, C., Doddapaneni, R., Patel, A.R., Singh, R., Mercer, R., Singh, M., Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma. Pharm. Res. 33:1 (2015), 137–154.
8. [8] Godugu, C., Patel, A.R., Desai, U., Andey, T., Sams, A., Singh, M., AlgiMatrix based 3D cell culture system as an in-vitro tumor model for anticancer studies. PLoS ONE, 8(1), 2013, e53708.
9. [9] Godugu, C., Patel, A.R., Doddapaneni, R., Marepally, S., Jackson, T., Singh, M., Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models. J. Control. Release 172:1 (2013), 86–95.
10. [10] Godugu, C., Patel, A.R., Doddapaneni, R., Somagoni, J., Singh, M., Approaches to improve the oral bioavailability and effects of novel anticancer drugs berberine and betulinic acid. PLoS ONE, 9(3), 2014, e89919.
11. [11] Goldberg, A.A., Draz, H., Montes-Grajales, D., Olivero-Verbel, J., Safe, S.H., Sanderson, J.T., 3,3′-Diindolylmethane (DIM) and its ring-substituted halogenated analogs (ring-DIMs) induce differential mechanisms of survival and death in androgen-dependent and -independent prostate cancer cells. Genes Cancer 6:5–6 (2015), 265–280.
12. [12] Gupta, S.C., Patchva, S., Aggarwal, B.B., Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 15:1 (2013), 195–218.
13. [13] Jamdade, V.S., Sethi, N., Mundhe, N.A., Kumar, P., Lahkar, M., Sinha, N., Therapeutic targets of triple-negative breast cancer: a review. Br. J. Pharmacol. 172:17 (2015), 4228–4237.
14. [14] Jellinck, P.H., Makin, H.L., Sepkovic, D.W., Bradlow, H.L., Influence of indole carbinols and growth hormone on the metabolism of 4-androstenedione by rat liver microsomes. J. Steroid Biochem. Mol. Biol. 46:6 (1993), 791–798.
15. [15] Lee, W.H., Loo, C.Y., Young, P.M., Traini, D., Mason, R.S., Rohanizadeh, R., Recent advances in curcumin nanoformulation for cancer therapy. Expert Opin. Drug Deliv. 11:8 (2014), 1183–1201.
16. [16] Lei, P., Abdelrahim, M., Cho, S.D., Liu, X., Safe, S., Structure-dependent activation of endoplasmic reticulum stress-mediated apoptosis in pancreatic cancer by 1,1-bis(3′-indoly)-1-(p-substituted phenyl)methanes. Mol. Cancer Ther. 7:10 (2008), 3363–3372.
17. [17] Liu, Y., Wang, L., Zhao, Y., He, M., Zhang, X., Niu, M., Feng, N., Nanostructured lipid carriers versus microemulsions for delivery of the poorly water-soluble drug luteolin. Int. J. Pharm. 476:1–2 (2014), 169–177.
18. [18] McClements, D.J., Li, F., Xiao, H., The nutraceutical bioavailability classification scheme: classifying nutraceuticals according to factors limiting their oral bioavailability. Annu. Rev. Food Sci. Technol. 6 (2015), 299–327.
19. [19] O'Toole, S.A., Beith, J.M., Millar, E.K., West, R., McLean, A., Cazet, A., Swarbrick, A., Oakes, S.R., Therapeutic targets in triple negative breast cancer. J. Clin. Pathol. 66:6 (2013), 530–542.
20. [20] Okonogi, S., Riangjanapatee, P., Physicochemical characterization of lycopene-loaded nanostructured lipid carrier formulations for topical administration. Int. J. Pharm. 478:2 (2015), 726–735.
21. [21] Palange, A.L., Di Mascolo, D., Carallo, C., Gnasso, A., Decuzzi, P., Lipid-polymer nanoparticles encapsulating curcumin for modulating the vascular deposition of breast cancer cells. Nanomedicine 10:5 (2014), 991–1002.
22. [22] Patel, A.R., Godugu, C., Wilson, H., Safe, S., Singh, M., Evaluation of spray BIO-Max DIM-P in dogs for oral bioavailability and in Nu/nu mice bearing orthotopic/metastatic lung tumor models for anticancer activity. Pharm. Res. 32:7 (2015), 2292–2300.
23. [23] Patlolla, R.R., Chougule, M., Patel, A.R., Jackson, T., Tata, P.N., Singh, M., Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J. Control. Release 144:2 (2010), 233–241.
24. [24] Qi, R., Li, Y.Z., Chen, C., Cao, Y.N., Yu, M.M., Xu, L., He, B., Jie, X., Shen, W.W., Wang, Y.N., van Dongen, M.A., Liu, G.Q., Banaszak Holl, M.M., Zhang, Q., Ke, X., G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol. J. Control. Release 210 (2015), 160–168.
25. [25] Ratnam, D.V., Chandraiah, G., Meena, A.K., Ramarao, P., Kumar, M.N., The co-encapsulated antioxidant nanoparticles of ellagic acid and coenzyme Q10 ameliorates hyperlipidemia in high fat diet fed rats. J. Nanosci. Nanotechnol. 9:11 (2009), 6741–6746.
26. [26] Reed, G.A., Arneson, D.W., Putnam, W.C., Smith, H.J., Gray, J.C., Sullivan, D.K., Mayo, M.S., Crowell, J.A., Hurwitz, A., Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,3′-diindolylmethane. Cancer Epidemiol. Biomarkers Prev. 15:12 (2006), 2477–2481.
27. [27] Reed, G.A., Sunega, J.M., Sullivan, D.K., Gray, J.C., Mayo, M.S., Crowell, J.A., Hurwitz, A., Single-dose pharmacokinetics and tolerability of absorption-enhanced 3,3′-diindolylmethane in healthy subjects. Cancer Epidemiol. Biomarkers Prev. 17:10 (2008), 2619–2624.
28. [28] Shakeri, A., Sahebkar, A., Nanotechnology: a successful approach to improve oral bioavailability of phytochemicals. Recent Pat. Drug Deliv. Formul. 10:1 (2016), 4–6.
29. [29] Shete, H.K., Selkar, N., Vanage, G.R., Patravale, V.B., Tamoxifen nanostructured lipid carriers: enhanced in vivo antitumor efficacy with reduced adverse drug effects. Int. J. Pharm. 468:1–2 (2014), 1–14.
30. [30] Siddiqui, J.A., Singh, A., Chagtoo, M., Singh, N., Godbole, M.M., Chakravarti, B., Phytochemicals for breast cancer therapy: current status and future implications. Curr. Cancer Drug Targets 15:2 (2015), 116–135.
31. [31] Thanki, K., Gangwal, R.P., Sangamwar, A.T., Jain, S., Oral delivery of anticancer drugs: challenges and opportunities. J. Control. Release 170:1 (2013), 15–40.
32. [32] Tran, T.H., Ramasamy, T., Truong, D.H., Choi, H.G., Yong, C.S., Kim, J.O., Preparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement. AAPS PharmSciTech 15:6 (2014), 1509–1515.
33. [33] Vanderlaag, K., Su, Y., Frankel, A.E., Burghardt, R.C., Barhoumi, R., Chadalapaka, G., Jutooru, I., Safe, S., 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes induce autophagic cell death in estrogen receptor negative breast cancer. BMC Cancer, 10, 2010, 669.
34. [34] Vanderlaag, K., Su, Y., Frankel, A.E., Grage, H., Smith, R. 3rd, Khan, S., Safe, S., 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit proliferation of estrogen receptor-negative breast cancer cells by activation of multiple pathways. Breast Cancer Res. Treat. 109:2 (2008), 273–283.
35. [35] Wahba, H.A., El-Hadaad, H.A., Current approaches in treatment of triple-negative breast cancer. Cancer Biol. Med. 12:2 (2015), 106–116.
36. [36] York, M., Abdelrahim, M., Chintharlapalli, S., Lucero, S.D., Safe, S., 1,1-bis(3’-indolyl)-1-(p-substitutedphenyl)methanes induce apoptosis and inhibit renal cell carcinoma growth. Clin. Cancer Res. 13:22 Pt 1 (2007), 6743–6752.